Table 2.
Multivariate COX analysis of HSPG2 and BLCA prognosis
| OS | DSS | PFI | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||||||
| Characteristics | Total(N) | HR(95% CI) | P value | HR(95% CI) | P value | Total(N) | HR(95% CI) | P value | HR(95% CI) | P value | Total(N) | HR(95% CI) | P value | HR(95% CI) | P value |
| Pathologic T stage | 377 | 364 | 378 | ||||||||||||
| T1 | 5 | Reference | Reference | 5 | Reference | Reference | 5 | Reference | Reference | ||||||
| T2 | 118 |
5,916,824.2028 (0.000—Inf) |
0.993 |
2,532,492.7659 (0.000—Inf) |
0.997 | 118 |
5,903,041.0662 (0.000—Inf) |
0.994 |
2,105,780.4302 (0.000—Inf) |
0.998 | 118 |
0.397 (0.140—1.122) |
0.081 |
28,350,182.8668 (0.000—Inf) |
0.999 |
| T3 | 195 | 11,004,504.7767 (0.000—Inf) | 0.992 |
3,302,267.1043 (0.000—Inf) |
0.997 | 184 |
11,068,411.8048 (0.000—Inf) |
0.994 |
2,348,989.5659 (0.000—Inf) |
0.998 | 196 |
0.774 (0.284—2.110) |
0.617 |
54,521,478.9483 (0.000—Inf) |
0.999 |
| T4 | 59 | 16,681,977.3123 (0.000—Inf) | 0.992 |
2,797,375.5060 (0.000—Inf) |
0.997 | 57 |
17,223,959.9614 (0.000—Inf) |
0.993 |
2,618,174.4008 (0.000—Inf) |
0.998 | 59 |
1.344 (0.475—3.806) |
0.577 |
33,987,351.8957 (0.000—Inf) |
0.999 |
| Pathologic N stage | 367 | 355 | 368 | ||||||||||||
| N0 | 238 | Reference | Reference | 232 | Reference | Reference | 238 | Reference | Reference | ||||||
| N1 | 46 |
1.844 (1.189—2.857) |
0.006 |
1.128 (0.417—3.053) |
0.813 | 45 | 2.754 (1.662—4.563) | < 0.001 |
1.324 (0.385—4.554) |
0.656 | 46 |
2.377 (1.537—3.676) |
< 0.001 |
0.745 (0.278—2.000) |
0.560 |
| N2 | 77 |
2.534 (1.781—3.606) |
< 0.001 |
2.080 (0.815—5.313) |
0.126 | 72 | 3.437 (2.229—5.299) | < 0.001 |
3.578 (1.160—11.034) |
0.027 | 77 |
2.931 (2.031—4.232) |
< 0.001 |
2.523 (0.968—6.579) |
0.058 |
| N3 | 6 |
2.410 (0.759—7.654) |
0.136 |
5.035 (0.296—85.67) |
0.264 | 6 | 4.133 (1.279—13.35) | 0.018 |
37.956 (1.587—907.8) |
0.025 | 7 |
7.438 (2.969—18.63) |
< 0.001 | 52.294 (5.092—537.1) | < 0.001 |
| Pathologic M stage | 212 | 207 | 212 | ||||||||||||
| M0 | 201 | Reference | Reference | 196 | Reference | Reference | 201 | Reference | Reference | ||||||
| M1 | 11 |
3.112 (1.491—6.493) |
0.002 |
0.354 (0.070—1.781) |
0.208 | 11 | 4.171 (1.874—9.282) | < 0.001 |
0.089 (0.011—0.707) |
0.022 | 11 |
6.416 (3.099—13.286) |
< 0.001 |
0.269 (0.047—1.547) |
0.141 |
| Histologic grade | 408 | 394 | 409 | ||||||||||||
| High grade | 387 | Reference | 373 | Reference | 388 | Reference | Reference | ||||||||
| Low grade | 21 |
0.338 (0.084—1.365) |
0.128 | 21 | 0.464 (0.114—1.884) | 0.283 | 21 |
0.274 (0.068—1.107) |
0.069 |
0.000 (0.000—Inf) |
0.998 | ||||
| Primary therapy outcome | 355 | 352 | 355 | ||||||||||||
| PD | 70 | Reference | Reference | 69 | Reference | Reference | 70 | Reference | Reference | ||||||
| SD | 30 |
0.555 (0.325—0.949) |
0.031 |
0.492 (0.139—1.739) |
0.271 | 30 |
0.476 (0.267—0.848) |
0.012 |
0.278 (0.064—1.207) |
0.087 | 30 |
0.623 (0.384—1.012) |
0.056 |
0.803 (0.288—2.241) |
0.676 |
| PR | 22 |
0.697 (0.398—1.218) |
0.205 |
0.916 (0.255—3.297) |
0.893 | 21 |
0.740 (0.416—1.317) |
0.306 |
0.649 (0.162—2.601) |
0.542 | 22 |
0.542 (0.315—0.933) |
0.027 |
0.708 (0.207—2.422) |
0.582 |
| CR | 233 |
0.155 (0.105—0.228) |
< 0.001 |
0.202 (0.074—0.547) |
0.002 | 232 |
0.074 (0.045—0.120) |
< 0.001 |
0.068 (0.020—0.235) |
< 0.001 | 233 |
0.099 (0.068—0.145) |
< 0.001 |
0.102 (0.040—0.260) |
< 0.001 |
| Gender | 411 | 397 | 412 | ||||||||||||
| Female | 108 | Reference | 102 | Reference | 108 | Reference | |||||||||
| Male | 303 |
0.868 (0.629—1.198) |
0.390 | 295 |
0.877 (0.593—1.296) |
0.510 | 304 |
0.911 (0.655—1.266) |
0.578 | ||||||
| Age | 411 | 397 | 412 | ||||||||||||
| < = 70 | 231 | Reference | Reference | 224 | Reference | 232 | Reference | ||||||||
| > 70 | 180 |
1.424 (1.064—1.906) |
0.018 |
0.999 (0.469—2.125) |
0.997 | 173 |
1.031 (0.721—1.474) |
0.868 | 180 |
1.066 (0.791—1.435) |
0.676 | ||||
| BMI | 361 | 351 | 362 | ||||||||||||
| < = 25 | 151 | Reference | 146 | Reference | 152 | Reference | |||||||||
| > 25 | 210 |
1.000 (0.721—1.386) |
0.998 | 205 |
1.069 (0.718—1.591) |
0.743 | 210 |
1.073 (0.776—1.484) |
0.669 | ||||||
| Subtype | 406 | 392 | 407 | ||||||||||||
| Non-Papillary | 273 | Reference | Reference | 263 | Reference | Reference | 273 | Reference | Reference | ||||||
| Papillary | 133 | 0.690 (0.487—0.976) | 0.036 |
1.625 (0.663—3.980) |
0.288 | 129 |
0.579 (0.372—0.900) |
0.015 |
2.256 (0.709—7.184) |
0.168 | 134 |
0.652 (0.459—0.926) |
0.017 |
1.494 (0.636—3.509) |
0.357 |
| Lymphovascular invasion | 280 | 272 | 281 | ||||||||||||
| No | 129 | Reference | Reference | 126 | Reference | Reference | 129 | Reference | Reference | ||||||
| Yes | 151 |
2.247 (1.547—3.263) |
< 0.001 |
1.999 (0.825—4.844) |
0.125 | 146 |
2.975 (1.846—4.792) |
< 0.001 |
2.162 (0.692—6.756) |
0.185 | 152 |
2.313 (1.587—3.373) |
< 0.001 |
1.090 (0.478—2.483) |
0.838 |
| Smoker | 398 | 385 | 399 | ||||||||||||
| No | 109 | Reference | 105 | Reference | 109 | Reference | |||||||||
| Yes | 289 |
1.306 (0.923—1.849) |
0.132 | 280 |
1.302 (0.857—1.977) |
0.216 | 290 |
1.145 (0.818—1.603) |
0.430 | ||||||
| Radiation therapy | 385 | 374 | 386 | ||||||||||||
| No | 364 | Reference | 353 | Reference | 365 | Reference | |||||||||
| Yes | 21 |
0.967 (0.475—1.968) |
0.926 | 21 |
1.018 (0.448—2.316) |
0.966 | 21 |
1.256 (0.662—2.381) |
0.485 | ||||||
| HSPG2 | 411 | 397 | 412 | ||||||||||||
| Low | 206 | Reference | Reference | 200 | Reference | Reference | 206 | Reference | Reference | ||||||
| High | 205 |
1.654 (1.228—2.229) |
< 0.001 |
2.204 (1.055—4.604) |
0.036 | 197 |
1.727 (1.203—2.481) |
0.003 |
2.693 (1.021—7.100) |
0.045 | 206 |
1.445 (1.074—1.942) |
0.015 |
2.392 (1.159—4.934) |
0.018 |